Pharmacokinetic/pharmacodynamic profile of voriconazole

Clinical Pharmacokinetics

Volumn 45, Issue 7, 2006, Pages 649-663

  Theuretzbacher, Ursula ^a   Ihle, Franziska ^b   Derendorf, Hartmut ^b,c  

^a Center For Anti Infective Agents Vienna   (Austria)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; EFAVIRENZ; ERGOT ALKALOID; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHADONE; OMEPRAZOLE; PHENYTOIN; PIMOZIDE; PREDNISOLONE; PROTEINASE INHIBITOR; QUINIDINE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; SULFONYLUREA; TACROLIMUS; UNINDEXED DRUG; VINCA ALKALOID; VORICONAZOLE; WARFARIN;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLUS; CANDIDA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG URINE LEVEL; ERYTHEMA MULTIFORME; FOOD DRUG INTERACTION; HEPATITIS; HUMAN; LIVER FAILURE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; PHOTODERMATOSIS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RASH; REVIEW; SEX DIFFERENCE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VISUAL DISORDER;

ANIMALS; ANTIFUNGAL AGENTS; BIOTRANSFORMATION; DRUG INTERACTIONS; FUNGI; HALF-LIFE; HUMANS; MYCOSES; PROTEIN BINDING; PYRIMIDINES; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 33745632766     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645070-00002     Document Type: Review

References (62)

1. Boucher HW, Groll AH, Chiou CC, et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-20
2. Patterson TF. Voriconazole: a viewpoint. Drugs 2002; 62: 2665-6
3. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53
4. Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56 Suppl. 1: 10-6
5. Purkins L, Wood N, Greenhalgh K, et al. The pharmacokinetics and safety of intravenous voriconazole: a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 2003; 56 Suppl. 1: 2-9
6. Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42: 395-402
7. Jeu L, Piacenti FJ, Lyakhovetskiy AG, et al. Voriconazole. Clin Ther 2003; 25: 1321-81
8. Pfizer Inc. Label: voriconazole for injection, tablets, oral suspension: LAB-0271-12; 2005 Mar
9. Robatel C, Rusca M, Padoin C, et al. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. J Antimicrob Chemother 2004; 54: 269-70
10. Craig WA, Suh B. Protein binding and the antimircobial effects: methods for the determination of protein binding. In: Lorian V, editor. Antibiotics in laboratory medicine. Philadelphia (PA): Lippincott Williams & Wilkins, 1991: 367-402
11. Zhanel GG, Saunders DG, Hoban DJ, et al. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother 2001; 45: 2018-22
12. Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48: 137-42
13. Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1193-9
14. Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003; 47: 3165-9
15. Pearson MM, Rogers PD, Cleary JD, et al. Voriconazole: a new triazole antifungal agent. Ann Pharmacother 2003; 37: 420-32
16. Groll A, Petraitiene R, Petraitis V, et al. Differential intrapulmonary distribution of voriconazole and liposomal amphotericin B in noninfected rabbits. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago (IL)
17. Lopes Bezerra LM, Filler SG. Interactions of Aspergillus fumigatus with endothelial cells: internalisation, injury and stimulation of tissue factor activity. Blood 2004; 103: 2143-9
18. Luque IG, Hernández AP, Ballesta S, et al. Intracellular penetration and activity of voriconazole in human polymorphonuclear leukozytes. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago (IL)
19. Ballesta S, Garcia I, Perea EJ, et al. Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J Antimicrob Chemother 2005; 55: 785-7
20. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31: 540-7
21. Roffey SJ, Cole S, Comby P, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003; 31: 731-41
22. Inoue K, Yamazaki H, Imiya K, et al. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 1997; 7: 103-13
23. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-7
24. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23
25. Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002; 11: 409-29
26. Purkins L, Wood N, Kleinermans D, et al. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003; 56 Suppl. 1: 17-23
27. Donnelly JP, De Pauw BE. Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect 2004; 10 Suppl. 1: 107-17
28. Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant 2004; 10: 73-90
29. Ally R, Schürmann D, Kreisel W, et al. Randomized, double blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophagteal candidiasis in immunocompromised patients. Clin Microbiol Infect Dis 2001; 33: 1447-54
30. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34
31. Vandecasteele SJ, Van Wijngaerden E, Peetermans WE. Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole. Eur J Clin Microbiol Infect Dis 2004; 23: 656-7
32. Drusano GL. How does a patient maximally benefit from anti-infective chemotherapy? Clin Microbiol Infect Dis 2004; 39: 1245-6
33. Andes D. Clinical pharmacodynamics of antifungals. Infect Dis Clin North Am 2003; 17: 635-49
34. Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards [NCCLS]). Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard second edition M27-A2. Wayne (PA): NCCLS, 2002
35. Drago M, Scaltrito MM, Morace G. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur J Clin Microbiol Infect Dis 2004; 23: 619-24
36. Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS antifungal surveillance program conducted in 2001 and 2002. J Clin Microbiol 2004; 42: 3142-6
37. Messer SA, Kirby JT, Sader HS, et al. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother 2004; 54: 1051-6
38. Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623-6
39. Pfaller MA, Diekema DJ, Messer SA, et al. Activities of fluconazole and voriconazole against 1586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 2003; 41: 1440-6
40. Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards [NCCLS]). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard M38-A. Standards Vol. 22 No. 16. Wayne (PA): NCCLS, 2002
41. Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032-7
42. Gil-Lamaignere C, Hess R, Salvenmoser S. Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. J Antimicrob Chemother 2005; 55: 1016-9
43. Müller M, de la Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother. 2004; 48: 369-77
44. Burgess DS, Hastings RW, Summers KK, et al. Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans. Diagn Microbiol Infect Dis 2000; 36: 13-8
45. Klepser ME, Malone D, Lewis RE, et al. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 2000; 44: 1917-20
46. Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004; 17: 268-80
47. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998; 42: 3018-21
48. Varanasi NL, Baskaran I, Alangaden GJ, et al. Novel effect of voriconazole on conidiation of Aspergillus species. Int J Antimicrob Agents 2004; 23: 72-9
49. Chandrasekar PH, Cutright J, Manavathu E. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J Antimicrob Chemother 2000; 45: 673-6
50. Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of voriconazole in a guinea pig model of disseminated invasive Aspergillosis. Antimicrob Agents Chemother 2000; 44: 2865-8
51. Murphy M, Bernard EM, Ishimaru T, et al. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1997; 41: 696-8
52. George D, Miniter P, Andriole VT. Efficacdy of UK-109,496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1996; 40: 86-91
53. Ghannoum MA, Okogbule-Wonodi I, Bhat N, et al. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphetericin B against hemtogenous Candida krusei infection in neutropenic guinea pig model. J Chemother 1999; 11: 34-9
54. Chryssanthou E, Sjolin J. Post-antifungal effect of amphotericin B and voriconazole against Aspergillus fumigatus analysed by an automated method based on fungal CO2 production: dependence on exposure time and drug concentration. J Antimicrob Chemother 2004; 54: 940-3
55. Manavathu EK, Ramesh MS, Baskaran I, et al. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004; 53: 386-9
56. Garcia MT, Llorente MT, Lima JE, et al. Activity of voriconazole: post-antifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. Scand J Infect Dis 1999; 31: 501-4
57. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42: 1105-9
58. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999; 43: 2116-20
59. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-58
60. Lee SC, Fung CP, Huang JS, et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000; 44: 2715-8
61. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rational for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12
62. Kullberg B, Pappas P, Ruhnke M, et al. Voriconazole compared with a strategy of amphotericin B followed by fluconazole of candidaemia in non-neutropenic patients [abstract no. O245]. 14th European Congress of Microbiology and Infectious Diseases; 2004 May 1-4; Prague